Spotlight -

Drug Development|

Quality Systems

Stephanie Sproule

Stephanie Sproule is a member. of the USP M&DQ EC.

Articles by Stephanie Sproule

Paulista/stock.adobe.com – For high-risk analytical procedures, control-chart monitoring of selected performance data can provide early warning of changes in performance.

Ongoing Analytical Procedure Performance Verification—Stage 3 of USP<1220>

ByPhil Borman,Amanda Guiraldelli Mahr,Jane Weitzel,Sarah Thompson,Joachim Ermer,Stephanie Sproule,Jean-Marc Roussel,Jaime Marach,Horacio Pappa

March 2nd 2023

Analytical procedure performance can be continually verified by risk-based monitoring of performance related data.

Latest Updated Articles

Ongoing Analytical Procedure Performance Verification—Stage 3 of USP<1220>
March 2nd 2023

Trending on Pharmaceutical Technology

Can AI Agents Satisfy CGMP Documentation Requirements?

Introducing the "PharmTech AI Pulse Check" Expert Video Series

PharmTech Weekly Roundup—September 18, 2026

Spray Drying Capacity Signals Faster Paths for Poorly Soluble Drugs

Q&A: How Can Sponsors Respond to Clinical Trial Customs Delays?